Merck-Google Cloud AI alliance exposes systemic data monopolies and erodes public health sovereignty

Indigenous knowledge systems, such as those in the Amazon or Himalayas, have long contributed to drug discovery (e.g., quinine from cinchona bark, aspirin from willow bark), yet these contributions are erased in AI-driven pharmaceutical research. The Merck-Google partnership risks deepening the erasure of such knowledge by prioritizing proprietary data models over open, community-based innovation. Traditional healers, who often serve as the first line of healthcare in many cultures, are systematically excluded from these alliances, reinforcing a top-down, corporate-controlled model of health innovation.

The Merck-Google alliance mirrors historical patterns of medical colonialism, where Western corporations extracted resources and knowledge from the Global South with minimal compensation or recognition. The 1991 neem tree patent dispute and the 2001 South African AIDS drug crisis highlight how pharmaceutical giants have repeatedly prioritized profits over public health, a dynamic that continues today. The partnership also echoes the 19th-century patent medicine industry, where unregulated claims and monopolistic practices led to widespread harm before regulatory reforms. These precedents suggest that without structural safeguards, AI-driven healthcare could repeat these failures at scale.

In many Indigenous and non-Western societies, health is not an individual commodity but a collective and ecological responsibility, as seen in the Māori concept of *whanaungatanga* (relationships) or the Andean principle of *buen vivir* (living well). The Merck-Google model, which treats health data as a proprietary asset, clashes with these frameworks, reducing complex biological and social systems to algorithmic inputs. Cross-cultural comparisons reveal that societies with strong communal health traditions (e.g., Kerala’s public health model in India) achieve better outcomes at lower costs than privatized systems, yet these models are ignored in favor of Silicon Valley’s extractive innovation paradigm.

AI in healthcare promises efficiency gains, but its application in drug discovery is constrained by biased training data, lack of transparency, and the 'black box' problem, where algorithms make decisions without explainability. Studies show that AI models trained on Western datasets often perform poorly on non-Western populations, exacerbating health inequities. The Merck-Google partnership risks accelerating these issues by centralizing medical knowledge in the hands of a few corporations, rather than fostering open, peer-reviewed research. Without rigorous validation and regulatory oversight, AI-driven drug discovery could introduce new risks, including algorithmic bias and unintended consequences.

Artistic and spiritual traditions often frame health as a balance between body, mind, and environment, a holistic view that contrasts with the mechanistic, data-driven approach of the Merck-Google alliance. For example, the Japanese concept of *ikigai* (a sense of purpose) or the African *sankofa* (learning from the past) offer alternative frameworks for understanding wellness that are incompatible with corporate health data extraction. Creative resistance to such alliances is emerging in artivism, where communities use storytelling and visual art to challenge the commodification of health, as seen in the #DataSovereignty movement in Latin America.

If unchecked, the Merck-Google partnership could lead to a future where healthcare innovation is controlled by a handful of tech-pharma conglomerates, with public health systems reduced to data suppliers for corporate algorithms. Scenario modeling suggests this could exacerbate global health disparities, as low-income countries become dependent on Western-owned AI tools for drug discovery and treatment recommendations. Conversely, a future where open-source AI and community-led health data systems are prioritized could democratize innovation, as seen in initiatives like the *Open Source Pharma Foundation* in India. The alliance also raises ethical questions about the long-term implications of AI in healthcare, including the risk of algorithmic determinism and the erosion of patient autonomy.

Marginalized communities—such as patients in low-income countries, indigenous groups, and public health workers—are entirely absent from the Merck-Google narrative, despite bearing the brunt of its potential consequences. For example, in Sub-Saharan Africa, where Merck already operates, local healthcare providers and patients have no say in how their data is used or monetized by Western corporations. The partnership also sidelines the voices of healthcare workers in public systems, who are increasingly pressured to adopt corporate technologies that may not align with their patients' needs. Without inclusive governance, such alliances risk deepening the digital divide in global health, leaving the most vulnerable populations further behind.